罗泊替尼

Description

Ropotrectinib · CAS 1802220-02-5 · C18H18FN5O2. UNII 08O3FQ4UNP.

Identification

CAS Registry Number	1802220-02-5
PubChem CID	135565923
Molecular formula	C18H18FN5O2
IUPAC name	(3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one
UNII (FDA)	08O3FQ4UNP

Computed Descriptors

Molecular Weight	355.4
XLogP3	2.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	0
Exact Mass	355.14445300
Monoisotopic Mass	355.14445300
Topological Polar Surface Area	80.6
Heavy Atom Count	26
Formal Charge	0

Documented Uses

• Repotrectinib is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). It is also indicated in patients ≥12 years of age and older with neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors which are locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have experienced disease progression following treatment or have no satisfactory alternative.
• Repotrectinib is a small molecule inhibitor of the proto-oncogene tyrosine-protein kinase ROS1 and of tropomyosin receptor tyrosine kinases (TRK-A, -B and -C) and is used to treat adults with non-small cell lung cancer. Repotrectinib is associated with a moderate rate of mild transient elevations in serum aminotransferase levels during therapy but has not been linked to episodes of clinically apparent liver injury with jaundice.
• Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors
• Repotrectinib is approved to treat:
• • Non-small cell lung cancer that has spread and has an abnormal ROS1 gene. It is used in adults.
• • Solid tumors that have an NTRK gene fusion. It is used in adults and children aged 12 years and older whose cancer has spread or cannot be removed by surgery and got worse after other treatment or cannot be treated with other therapies.¹

Synonyms

Repotrectinib; 1802220-02-5; TPX-0005; Augtyro; 08O3FQ4UNP; repotrectinibum; (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE; (3R,6S,)-45-Fluoro-3,6-dimethyl-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenanonaphan-9-one; RefChem:178876; Multikinase Inhibitor TPX-0005; Multi-kinase Inhibitor TPX-0005; ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005; Ropotrectinib; Repotrectinib [USAN]; TPX0005; Repotrectinib(TPX-005)

Frequently Asked Questions

What are the CAS number and molecular formula of Ropotrectinib?

CAS 1802220-02-5; molecular formula C18H18FN5O2; molecular weight — g/mol.

What other names is Ropotrectinib known by?

Repotrectinib, 1802220-02-5, TPX-0005, Augtyro, 08O3FQ4UNP, repotrectinibum.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.